Highbridge Capital Management’s Abeona Therapeutics ABEO Stock Holding History

Highbridge Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-17,000	Closed	-$6.1M	–	864
2018 Q1	$6.1M	Hold	17,000	–	–	0.1%	253
2017 Q4	$6.74M	Sell	17,000 -3,000	-15%	-$1.24M	0.12%	218
2017 Q3	$8.53M	Sell	20,000 -15,908	-44%	-$4.27M	0.13%	192
2017 Q2	$5.75M	Buy	35,908 +8,644	+32%	+$1.18M	0.09%	269
2017 Q1	$3.41M	Buy	27,264 +5,192	+24%	+$670K	0.05%	358
2016 Q4	$2.68M	Buy	22,072 +11,466	+108%	+$1.8M	0.05%	338
2016 Q3	$1.59M	Buy	+10,606	New	+$1.04M	0.03%	468

Other funds holding ABEO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Highbridge Capital Management's ABEO Position: Q2 2018 in Review

Highbridge Capital Management sold out of Abeona Therapeutics (ABEO) in Q2 2018, closing a stake of 17,000 shares — an estimated $6.1M sold.

Highbridge Capital Management first reported a position in ABEO in Q3 2016 and held it in 7 quarters. The position peaked at $8.53M in Q3 2017. 92 funds tracked by Wall St. Rank hold ABEO as of Q2 2018.

Highbridge Capital Management reported no remaining Abeona Therapeutics position as of Q2 2018 after selling out during the quarter.
Highbridge Capital Management sold 17,000 Abeona Therapeutics shares in Q2 2018, an estimated $6.1M.
Highbridge Capital Management first reported a position in Abeona Therapeutics in Q3 2016 and held it in 7 quarters.
Highbridge Capital Management's Abeona Therapeutics position peaked at $8.53M in Q3 2017.
92 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2018.

Based on Highbridge Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.